Iterative Scopes builds proprietary artificial intelligence and computer vision technologies to improve endoscopy interpretation, polyp detection and disease severity characterization in gastroenterology. Its product suite includes SKOUT, an automated polyp detection tool (CE marked in Europe; 510(k) submitted in November 2021) and an AI Recruitment service to accelerate IBD clinical trial enrollment. The company is also developing novel endoscopic scoring systems intended to provide more consistent, individualized measures of GI disease and to establish more meaningful endpoints for drug development and clinical care. Iterative Scopes was spun out of MIT in 2017 and is based in Cambridge, Massachusetts. The company plans to scale technical and clinical operations to accelerate product development and broaden clinical applications. Financially, it has been actively fundraising, having completed a Series A in August 2021 and announcing a new Series B to further its R&D and commercialization efforts. Iterative Scopes builds proprietary AI and computer-vision algorithms to extract and standardize insights from endoscopic videos for colorectal cancer and inflammatory bowel disease. Its initial products include SKOUT, a polyp detection algorithm, and technology that automates Mayo Endoscopic Score (MES) interpretation from colonoscopy videos. The company is aggregating longitudinal datasets by linking endoscopic data with genomic, molecular, and phenotypic information to enable predictive models for individualized therapeutic selection and novel trial endpoints. Iterative Scopes is pursuing commercial reach through an exclusive AI partnership with ProVation to integrate into community and academic GI workflows. It is also positioning its tools to help biopharma sponsors improve patient selection, reduce trial costs, and increase reproducibility of endpoints. The business recently completed a $30 million Series A to further develop its core algorithmic innovations and expand its life sciences offerings. Iterative Scopes is a software-only gastrointestinal data company spun out of MIT in 2017 that develops computer-vision AI toolkits for gastroenterology. Its core product applies computer vision analytics to complex endoscopy problems to deliver real-time actionable insights in the endoscopic suite. The team works with over 40 medical centers and hospitals to develop physician-centric models of care. The company closed a $5.2M seed round, bringing total funding to over $7M. The investment will support progress through clinical trials and commercialization of its proprietary computer vision technology in 2020. Management said it is on track to deliver a number of products into the gastrointestinal endoscopic suite working alongside physicians to improve patient outcomes.

Total raised

$185M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2022